A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection . . . Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Study Location:

Washington

Topic:

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02859558?term=ACTG+5354&rank=1

Coordinator:

Anna Wimpleberg

Enrollment:

Open

Trial Period:

Ongoing

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body. 

This study is trying to find out if starting antiretroviral drugs very early in HIV infection will change the following:

  • Limit the virus from getting into hidden areas of the body (“reservoirs”).
  • Change how the immune system helps to control the virus.

Men and women who:

  • Are at least 18 years old
  • Have had certain lab tests done that confirm very early HIV infection
  • Are willing to take antiretroviral drugs right away to treat HIV.

Categories

Location
Topic

Clinical Trials

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More